• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Association of survival benefit with docetaxel in prostate cancer and total number of cycles administered: a post hoc analysis of the Mainsail Study.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    559060.pdf
    Size:
    326.8Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    de Morrée, E
    Vogelzang, N
    Petrylak, D
    Budnik, N
    Wiechno, P
    Sternberg, C
    Doner, K
    Bellmunt, J
    Burke, J
    Ochoa de Olza, M
    Choudhury, Ananya
    Gschwend, J
    Kopyltsov, E
    Flechon, A
    van As, N
    Houede, N
    Barton, D
    Fandi, A
    Jungnelius, U
    Li, S
    Li, J
    de Wit, R
    Show allShow less
    Affiliation
    Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, the Netherlands
    Issue Date
    2016-08-25
    
    Metadata
    Show full item record
    Abstract
    The optimal total number of docetaxel cycles in patients with metastatic castration resistant prostate cancer (mCPRC) has not been investigated yet. It is unknown whether it is beneficial for patients to continue treatment upon 6 cycles.
    Citation
    Association of survival benefit with docetaxel in prostate cancer and total number of cycles administered: a post hoc analysis of the Mainsail Study. 2016, JAMA Oncol
    Journal
    JAMA Oncology
    URI
    http://hdl.handle.net/10541/619995
    DOI
    10.1001/jamaoncol.2016.3000
    PubMed ID
    27560549
    Type
    Article
    Language
    en
    ISSN
    2374-2445
    ae974a485f413a2113503eed53cd6c53
    10.1001/jamaoncol.2016.3000
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
    • Authors: Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K
    • Issue date: 2015 Apr
    • Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.
    • Authors: Vogelzang NJ, Fizazi K, Burke JM, De Wit R, Bellmunt J, Hutson TE, Crane E, Berry WR, Doner K, Hainsworth JD, Wiechno PJ, Liu K, Waldman MF, Gandhi A, Barton D, Jungnelius U, Fandi A, Sternberg CN, Petrylak DP
    • Issue date: 2017 Feb
    • Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    • Authors: Beer TM, Hotte SJ, Saad F, Alekseev B, Matveev V, Fléchon A, Gravis G, Joly F, Chi KN, Malik Z, Blumenstein B, Stewart PS, Jacobs CA, Fizazi K
    • Issue date: 2017 Nov
    • Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
    • Authors: Meisel A, von Felten S, Vogt DR, Liewen H, de Wit R, de Bono J, Sartor O, Stenner-Liewen F
    • Issue date: 2016 Mar
    • Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    • Authors: de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PFA, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW
    • Issue date: 2017 Apr
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.